3/11/2008 8:39:20 AM
AUSTIN, Texas & HYDERABAD, India--(BUSINESS WIRE)--Biotechnology companies Heparinex, L.L.C. and Choncept, L.L.C. announced today option and license agreements with Biological E., Limited (BE), a leading biopharmaceutical company based out of India. The agreement provides BE with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds. Heparinex and Choncept are funded and managed by life sciences venture firm Emergent Technologies, Inc., and both companies are headed by Chief Scientist Dr. Paul DeAngelis.
comments powered by